1. Hepatitis C (HCV) is a global epidemic and the main reason of causing the end-stage liver disease in many areas such as Europe, America and Japan. According to the latest investigation from World Health Organization (WHO), there are about 250 million people infected with the chronic HCV in the world, and the new cases increased by hundred thousand patients annually.

The HCV patients mainly accepted the treatment of long-acting interferon combined with ribavirin in the earlier past, which is named “PR” plan. Although the PR plan has cured lots of patients infected with HCV, there are still quite a few that can’t be treated. For instance, the patients with genotype 1 of HCV have the bad therapeutic response to the PR plan, meanwhile, some other patients couldn’t tolerate the side effects, especially the patients with decompensated cirrhosis have contraindications for interferon and ribavirin therapy. 

The issues of low cure rate, long period of the treatment, side effects and others promoted the rapid development of new drugs for HCV in the past years. By decrypting the lifecycle of HCV replication, some small molecule compounds were found directly acted on the "Non-structural proteins" in the process of the replication of HCV, and effectively inhibit the replication of HCV and achieve the purpose of eliminating HCV that these kinds of drugs were named "Direct antiviral drugs (DAA)."

2. The tumor disease has become the leading killer in all kinds of the diseases. In recent years, with the environmental pollution and urbanization caused by ageing society and industrialization, people’s lifestyle has been changed, and the morbidity rate and death rate are going up. At present, the therioma has become the No. 1 killer with more than 25% of mortality rate in China.

With the increase in the number of new targeted drugs and the decrease in the cost of drugs, and the extended coverage of medical insurance, there will be significant changes in the pattern of clinical use of tumor drugs in China. Under the encouraging policy of drug administration in innovative drugs, the CFDA has approved six kinds of small molecular targeted drugs in 2017. Those rapid increase of drug types will promote the continuous development of the proportion of targeted drugs in the overall treatments of tumors.

3. Diabetes is a kind of metabolic disease caused by the reason of hypoinsulinism or insensitivity of peripheral tissues to insulin, and characterized by persistent hyperglycemia. Diabetes may cause the long-term damage, and insufficiency or failure of various tissues and organs (such as eyes, kidneys, heart, blood vessels, nerves, etc). Due to the different pathogenesis of diabetes, it can be divided into type I diabetes, type II diabetes, gestational diabetes mellitus and other types of diabetes mellitus. Currently in China, only 25.8% of diabetes patients were under treated, while only 39.7% among these under-treated patients got blood sugar well controlled.

AB Pharma has been always committed to the R&D of new drugs and has already got significant breakthroughs and achievements in the global critical illness such as anti-infection, anti-tumor and endocrine diseases. We believe that AB Pharma will develop more and better innovative drugs and also serve better to the human society in near future. 

HCV is a single positive-strand ribonucleic acid (RNA) virus with about 9,400 nucleotides in the Flaviviridae familyand exhibits a very high degree of genetic diversity. According to internationally accepted methods, HCV is classified as six genotypes and more than 80 subtypeswith Arabic numerals for HCV genotypes and lowercase English letters for genotypes, such as 1a, 2b and 3c etc. Genotype 1 is globally distributed with more than 70% of all HCV patients. In China, the popular HCV genotypes have been classified as four genotypes 1, 2, 3 and 6, and the gene subtypes are mainly 1b and 2a. The first Chinese epidemiological investigation on HCV and human genetic polymorphism (CCgenos) led by People's Hospital of Peking University found that Genotype 1 was the most prevalent HCV genotype in the patients of Han nationality with 58.2 percentage, and thereinto subtype 1b accounted for 98 percentage.

AB Pharma is speeding up the clinical trials of the " all-genotypes efficient new drugs (ZN2007 and ZN6168) with double targets (NS3/4A and NS5A) against hepatitis C virus (HCV)", in order to make Chinese patients infected with HCV reallybenefit to use the original good Chinese anti-HCV drugs with curable, affordable, and international competitiveness developed independently by AB Pharma.

021-5442 6122
©2018 AB Pharma Ltd. All rights reserved
沪公网安备 33311802006333号 沪ICP备13019832号-1
Technical Support:www.51eway.com
No. 99, Lane 133, Guangzhong Road, Shanghai